Replicating DNA structures is key to faster gene therapy vector manufacturing says Touchlight

By Gareth Macdonald contact

- Last updated on GMT

iStock/HYWARDS
iStock/HYWARDS

Related tags: Dna

Replicating secondary structures in viral DNA could be key to developing to faster AAV vector production methods according to UK tech firm Touchlight.

Touchlight teamed with Cobra Biologics this week​, explaining that the idea is to make gene therapy vectors faster to produce to allow developers to move promising candidates into trials sooner.

Cobra CSO Dan Smith told us the project will “combine Cobra's Plasmid DNA service offering and experience with Touchlight’s 'doggybone DNA' technology to deliver a rapid and cost effective route to generate critical DNA starting material for the production of viral vectors for gene therapy products​.”

Doggybone DNA

This was echoed by Touchlight spokeswoman Sarah Milsom, who told us the firm’s in vitro​ dual enzyme process amplifies a circular template to produce DNA at commercial scale and quality.

“The first enzyme used is Phi29, which amplifies the DNA, generating and displacing long concatamers of DNA by rolling off the circular template. A protelomerase is then used to cleave and ligate the ends of the linear fragments containing the DNA sequences of interest.”

The product of Touchlight’s process is a closed linear construct known as a doggybone or dbDNA. This material can be fed back into the process as the starting material for further amplification.

Milsom told us in the Cobra collaboration “dbDNA encoding the components required for viral vector production will be transfected into cells to produce virus, replacing the plasmids which are traditionally used in this process."

Secondary structures

The approach has a number of advantages Milsom said, explaining that: “The process is very high yield whilst having a small footprint and no fixed equipment. It is a directly scalable process amenable to a closed automated system."

She added that: “​From a regulatory perspective, the acellular nature of the technology benefits from having no antibiotic resistance genes or bacterial sequences and very high purity. 

“However,” ​Milsom added “the most important benefit in terms of manufacturing virus is that our process can easily amplify the complicated secondary structures present in virus DNA (ITRs) that are otherwise very difficult to produce with the necessary fidelity.”

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us

Products

View more

Webinars